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Malignant melanoma is a skin cancer of which the incidence is said to be raising in recent 
years. Prevention may result in decrease of the incidence. Early detection may result in the 
detection of earlier stages of the disease. In Limburg a combined campaign of prevention 
and screening has been performed in recent years and its effects should be evaluated. 
Objectives 
To study time trends of malignant melanoma incidence and the evolution of stages of de-
tected melanomas and to relate them to interventions in previous years. 
Methods 
An ongoing multi-faceted intervention, including information as well as screening invitations 
(Euromelanoma project) was implemented in 1999. Time trends of malignant melanoma 
were studied on the basis of data from the Limburg Cancer Registry (LIKAR) of 1996-2005. 
Stages were studied on the basis of an additional clinical registration completed by patholo-
gists and dermatologists. 
Results 
Over the years 1996-2005, the crude incidence rate of malignant melanoma was 6.8/100,000 
patient-years in males and 11.6 in females, with a European standardized incidence rate 
(ESR) of 6.4 in males and 10.5 in females. The incidence progressively increased with age. 
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In males, the ESR initially decreased, followed by a significant increase from 3.0 in 1998 to 
7.6 in 2005. On average this is a yearly increase of 0.5 per 100,000 persons (p= 0.04). In 
females the curve fluctuates, resulting in almost similar rates in 1996 and 2004 (p=0.85), but 
with a sudden increase from 9.2 to 15.8 between 2004 and 2005.  
Neither the Breslow nor the Clarck classification showed any significant change over the reg-
istration period. The proportion of lymph node invasion, metastasis and ulcerations did not 
change.  
Discussion 
With the exception of a small and clinically irrelevant increase in ESR in males, no changes 
over time were detected in incidence or stage distribution. The effect of the intervention 
seems limited.  
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Introduction 
Malignant melanoma is a relatively rare malignancy of the skin that seems to become more 
frequent over the years (1). The main cause is considered to be skin burn in sensitive peo-
ple, especially in children (2), although most cancers will be detected above age 25 in 
females and age 35 in males (3). In far too many cases, melanomas are diagnosed in ad-
vanced stages and prognosis has been bad although it recently improved after the 
introduction of resection policies including a very broad zone of normal tissue. 
Starting in 1999, the provincial health authorities of the Belgian province of Limburg, together 
with regional health care workers and the funding organization TOKAP, adopted a compre-
hensive approach towards the population in order to prevent and detect melanomas early. 
The approach included sun protection information campaigns aimed at the population at 
large as well as at elective target groups, and yearly invitations for screening, within the 
framework of the Euromelanoma day. 
Information campaigns can only be expected to show results after decennia, unless the 
campaign also includes guidelines for self-examination of the skin and screening by physi-
cians, which is the case here. 
Yearly screening of the total population, including self-examination of the skin can be ex-
pected to result in a higher incidence during a period of two years (first round effect), 
followed by a gradual decrease towards the original level. As a total population screening is 
unrealistic, the initial increase will be spread over a much longer period, maybe ten years or 
more and the incidence peak will be much lower and therefore difficult to detect. Even in this 
case, however, it can be expected that melanomas will be detected earlier, resulting in the 
detection of tumours of an earlier stage.  
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After ten years of campaigning, we used data of the Limburg Cancer Registry (LIKAR) (3) as 
well as a more detailed additional registration of melanomas to evaluate the time trend of 
both the incidence and the distribution of the stages over the years and tried to relate this to 
the screening and prevention campaigns. 
Methods 
Design 
We used a time trend analysis, comparing yearly incidence figures and tumour stages of 
melanomas diagnosed between 1996 and 2005. 
Population 
Our data relate to the population of the Belgian province of Limburg, situated in the north-
east of Belgium. The territory covers 2422 km² or 7.9 % of the Belgian territory. On 1 January 
2001 the population totalled 791,178, of which 395,579 men and 395,599 women. The de-
gree of urbanisation is restricted: of the two largest cities Hasselt (n= 68,058 on 01/01/2001) 
and Genk (n= 62,842 on 01/01/2001) constitute 17% of the total population. Both are situated 
in the area of Central Limburg. Forty-four percent of the population lives in 32 municipalities 
with 20,000 inhabitants or less, and 39% in 10 municipalities with 20,000 to 40,000 inhabi-
tants (Figure1).  
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Interventions 
The intervention was designed and operationalised by a multidisciplinary group including 
physicians, funders, and policy makers. It was progressively built up over the last ten years, 
and included a number of methods (to be divided into patient information/primary prevention) 
and screening (and target groups): 
 The campaign called ‘Be sensible in the sun’ concentrated on taking appropriate precau-
tions to prevent the emergence of malignant melanomas. It included the production and 
distribution of leaflets, brochures, a sundial (recently also available on the website), post-
ers, postcards, sunscreen lotion labels, a sunscreen to be placed behind the windscreens 
of cars and lectures in different municipalities targeted at the general population.  
 Additional posters, postcards, leaflets, and a competition were addressed at camp lead-
ers, youth clubs, after-school childcare programmes, playground activities, sports clubs 
and event visitors. A question and answer game was used for class five primary school 
children as a waiting room activity during the school medical check-up.  
 An inspirational folder was sent to local authorities and a life-size sun dial was made 
available to stimulate them to add their own activities to the common action of the prov-
ince.  
 Adapted promotional materials were distributed through well-baby clinics. 
 A training course and a CD-ROM were developed for GPs. 
 Similar to elsewhere in Europe, from 1999 onwards, in Limburg the ‘Melanoma Monday’ 
was organised yearly in the first half of May, as a method to encourage the population 
and especially sensitive people to present themselves for a skin examination by a derma-
tologist free of charge (4). More than half of the Belgian dermatologists collaborate on the 
initiative. The yearly number of participating patients is between 4000 and 5000, without 
any specific trend. The number and percentage of positive cases have descended from 
25 (0.9%) in 1999 to 8 (0.2%) in 2003. 
Data collection 
Incidence rates were calculated from the LIKAR registry, which at the time of writing covers 
the years 1996-2005. The registry includes all cancers in inhabitants of the province of Lim-
burg, which have been histologically or cytologically confirmed. A detailed description of its 
methods and procedures has been published elsewhere (3). More detailed information on 
each tumour was directly recorded from the pathologist and the referring clinician, in general 
the dermatologist. Until the year 2001, cases were retrieved from LIKAR, and both the pa-
thologist and the clinician were asked to provide the additional information; from 2002 until 
2005 data were prospectively identified by the pathologist. As a result these data are avail-
able until the year 2005. 
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For each diagnosis of a malignant melanoma, the pathologist completed a form recording 
APO thickness, presence of tumour cells at the section margins, presence of ulceration, 
presence of micro metastasis and pathological TNM (pTNM) classification. The form was 
sent to the clinician, who was asked to add the location of the primary tumour, the Clark and 
Breslow stage, the AJCC and TNM classification and the presence of any known metastasis 
(5). All the involved physicians were informed about the goals of the project and the proce-
dure to be followed via the loco-regional quality evaluation groups (LOK). Each Belgian 
clinician has to be a member of one of these groups in order to keep their certification. The 
anonymity of each physician’s data towards the group was guaranteed.  
The whole project was validated by the ethical review board of the Belgian work against can-
cer. 
Outcome measures 
The TNM classification of malignant melanoma is presented in table 1, and incorporates 
three main prognostic features: tumour thickness (Breslow), anatomical Clark levels and the 
absence or presence of ulceration (5). 
Table 1: TNM classification of malignant melanoma 
T Classification 
pTis melanoma in situ (Clark level I)/severe melanocytic dysplasia 
pT1: -1.0 mm 
 a: without ulceration 
 b: with ulceration or level IV or V 
pT2:  1.01–2.0 mm 
 a: without ulceration 
 b: with ulceration 
pT3:  2.01–4.0 mm 
 a: without ulceration 
 b: with ulceration 
pT4: >4.0 mm 
 a: without ulceration 
 b: with ulceration 
N Classification 
pN0:  no regional lymph node metastasis 
pN1:  1 lymph node 
 a: micrometastasis 
 b: macrometastasis 
pN2:  2-3 lymph nodes 
 a: micrometastasis 
 b: macrometastasis 
 c: in-transit metastasis/satellite(s) without metastatic lymph nodes 
pN3:  4 or > metastatic lymph nodes, matted lymph nodes, or combinations of in-transit met(s)/satellite(s) and 
 metastatic lymph node(s) 
M Classification 
M1:  Distant skin, subcutaneous, or metastasis beyond the regional lymph nodes 
M2:  Lung metastasis 
M3:  All other visceral or any distant metastasis 
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The Breslow index is the tumour maximum vertical diameter from the top of the granular 
layer or ulcerated tumour surface to the deepest point of invasion. It is measured in millime-
ters. 
The Anatomical Clark level is categorised from I to V and subsequently includes the epithe-
lium only (I), the papillary dermis (II), the papillary-reticular interface (III), the reticular dermis 
(IV), and the subcutaneous fat (V). 
Ulceration (particularly if >3mm) is an independent adverse prognostic factor, with a ten-year 
survival of around 50% in case of ulceration versus 78% if non-ulcerated.  
Presence of tumour cells at the section margin or ulceration as seen during histological ex-
amination and known metastasis were recorded as either present or absent. 
Analysis 
For comparison, melanoma incidence rates have been stratified by gender and standardised 
for age according to the European standard population (ESR per 100,000 person-years). 
ESR values for males and females separately were linked to the year by simple linear re-
gression analysis. 
Tumour thickness and classifications were linked to the year by Kruskall-Wallis analysis 
(categorical dependent variable) or linear regression analysis (continuous dependent vari-
able) and by chi² testing or Kruskall-Wallis after categorisation of the years into three classes 
(1996-1999, 2000-2002, 2003-2005) (Table 2). 
Table 2: Depth and stage of the tumours according to three time periods 
Classification class 1996-1999 2000-2002 2003-2005 total 
      
Breslow (mm) <0.5  48  59  41  148 
 0.5-3  114  90  84  288 
 >3  21  30  21  72 
Clarck 1  12  19  11  42 
 2  36  41  36  113 
 3  67  42  54  163 
 4  48  58  38  144 
 5  11  11  9  31 
pN PN0  158  145  165  468 
 PN1  4  3  8  15 
 PN2  1  0  0  1 
 PN3  0  2  1  3 
pM PM0     
 PM1  14  4  7  25 




Over a period of ten years, LIKAR recorded 735 malignant melanomas, 271 in males and 
464 in females. This results in an overall crude incidence rate of 6.8/100,000 patient-years in 
males and 11.6 in females or an ESR of 6.4 in males and 10.5 in females. The incidence 
progressively increases with age (Figure 2). 












Figure 3: Time trend of the incidence (ESR/100,000 patient-years) of malignant melanoma  
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In males, the ESR initially decreased, followed by a steady and statistically significant in-
crease from 3.0 in 1998 to 7.6 in 2005. On average this is a yearly increase with 0.5 per 
100,000 persons (p= 0.04). The proportion of the variance in incidence explained by time is 
55%. In females the curve fluctuates, resulting in almost similar rates in 1996 and 2004 
(p=0.85), but with a sudden increase from 9.2 to 15.8 between 2004 and 2005 (Figure 3). 
Clinical registration 
Some detailed information was available for 601 patients. At least one measure of staging 
was available for 509 patients. There were 219 males and 362 females (gender missing in 20 
cases). Their mean age was 55 years (range 18-92). Mean age and sex ratio were stable 
over the three time periods that were analysed.  
There were 339 patients (56%) with a reported diagnosis of superficial spreading of malig-
nant melanoma, 96 (16%) with a nodular melanoma, 51 (9%) with a lentiginous melanoma, 
and 43 (7%) with an in situ malignant melanoma. All other types counted less than 3% each. 
There was no increasing or decreasing trend in the relative occurrence of the most frequent 
types over the three time periods.  
Staging 
Depth of the lesion according to Breslow was available for 509 patients. Overall the depth 
was less than 0.5mm, between 0.5 and 3mm and more than 3mm in 149 (29%), 293 (57%) 
and 73 (14%) cases, respectively. There was no relation between the depth and year of di-
agnosis (p=0.40), nor between depth and the three time periods (chi² p=0.23) (Figure 4).  
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The classification according to Clark was available for 493 patients. Over the years the rela-
tive frequency of the different Clark classes fluctuated heavily. There was no increasing or 
decreasing trend (regression, p=0.11) (Figure 5). Neither was there a relation between the 
proportion of Clark classes and the time periods (chi² p=0.23). 













1994 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
I II III IV V
 
Lymph node invasion was registered in 163 cases and present in 19 (12%). There was no 
time trend (ANOVA, p=0.23). Risk of lymph node invasion was not related to gender (chi², 
p=0.48) or age (ANOVA, p=0.87) 
Clinically known metastasis was present at the time of diagnosis in 25 (5%) cases. There 
was no relation between the proportion of metastases and gender (chi² p=0.69) or the year of 
diagnosis (ANOVA, p=0.19) (Figure 6). Risk of metastasis was significantly related, however, 
to increasing age (linear regression p= 0.003), although the effect was limited. The proportion 
of metastases explained by age (R²) was only 2%. 
Ulceration was registered in 388 cases and present in 80 (21%). There was no relation with 
gender (chi² p=0.68) or year of diagnosis (ANOVA p=0.86). Risk of ulceration increased 
slightly, however, with increasing age (p=0.002, R²=2%). 
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Figure 6: proportion of patients with a metastasis at the time of diagnosis 























The LIKAR ESRs for melanoma are lower compared to the recently published national data 
of 2005 (10.4 and 15.3 for males and females) (6). This may be caused by differences in reg-
istration procedures (LIKAR only includes tumours which are histologically or cytologically 
confirmed) or from a more rural population.  
With ESR values between 5 and 15 per 100,000 people and per year, malignant melanoma 
is in both males and females a reasonably rare tumour. Nevertheless, it strikes about 54,000 
people in Europe (1,2) every year, and 37,000 patients around the world die from it annually.  
This analysis was not intended and not able to measure the effect of the sun protection in-
formation part of our intervention. This can only be evaluated on a long term basis. However, 
we expected yearly screening of (part of) the population and encouraging people to perform 
self-examination of the skin to result in a temporary higher incidence of melanoma (first 
round effect), followed by a gradual decrease towards the original level. As a total population 
screening is unrealistic, this increase may be spread over a period of many years and the 
incidence peak may be low and therefore difficult to detect. Even in this case, however, we 
expected that melanomas would be detected earlier, resulting in a gradual evolution towards 
detecting tumours at an earlier stage.  
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In females we could not identify any significant time trend over the ten years of registration. 
This may be a result of either absence of such relation or of low numbers. However, combin-
ing the cases of three groups of three or four years also gives the same result, while this 
should result in sufficient power to detect any clinically relevant change. The sudden in-
crease in the year 2005 is considered to be coincidental and for the time being, neglected. In 
males, the ESR initially decreased, followed by a steady and statistically significant yearly 
increase of 0.46 per 100,000 persons (Figure 3). This increase means more than a doubling 
of the incidence over seven years, but absolute numbers are low and clinically this remains 
almost negligible. Over the whole of the ten years the trend even fades. A similar pattern has 
been identified in the registry of the Integrale kankerstichting Limburg (IKL) and Zuid (IKZ), 
our neighbours from just across the Dutch border (7). The increase may be the result from all 
information efforts, especially those encouraging people to have their skin examined on a 
regular basis. Similar results have been observed elsewhere. Janda et al. found significantly 
increasing screening rates, especially in men over 50, after a screening intervention in Aus-
tralia. Those men, who were more likely to be screened, had skin lesions removed previously 
or had identified personal risk factors for melanoma (8). We do not know if a similar pattern 
shows in our population. Moreover, in our view, this does not sufficiently explain the be-
tween-gender difference in trend.  
In spite of the yearly collaboration of more than half of the dermatologists, the impact of the 
Euromelanoma day seems very limited. This is understandable in view of the small number 
of tumours detected (4). 
Regarding the pathology distribution, most of the malignant melanomas were superficially 
spread (56%), 16 % percent presented with nodular melanoma. This distribution is compara-
ble with the literature (9). 
For the 509 patients whose Breslow index was noted, 29% percent had a Breslow index <0.5 
mm, 57% between 0.5 and 3 mm. It is obvious that the prognosis is better with less thick-
ness. Patients with tumours less than 0.76 mm thickness have a likelihood of recurrence of 
less than 1% in 10 year (10). We did not find a trend towards lesser Breslow thickness in our 
study, nor a lower Clark index after the screening campaign. So no trend towards a better 
prognosis of melanoma could be identified by our information and screening campaign. Here 
also, insufficient statistical power may be a problem for the initial analysis, but regrouping to 
three periods of three or for years did not change the picture.  
Because melanomas are rare tumours and physicians had to register a limited number of 
cases each, it was expected that they would be motivated to do so. We elaborated a user 
friendly registration map and introduced the melanoma registration project in the LOK, where 
physicians come together per discipline to discuss professional matters. It proved extremely 
difficult, however, to motivate the dermatologists to register. This part of the initial planning 
was therefore abandoned. On the contrary the technique of extracting the melanomas from 
the LIKAR-register, a working cancer register in the province, followed by enriching the data 
for each melanoma by interrogating the pathologists on the case was a much better ap-
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proach. It is important to collect the right and relevant data on each melanoma. So our regis-
tration form had to be complete, appealing and not too large or difficult to fill in. We therefore 
did not ask for the number of mitoses in the tissue sample, an item we probably will include 
in the dataset in the future.  
Our study was intended to be a first step to an ongoing tumour-specific register for melano-
mas that would enable us to follow the evolution of the melanomas in our province. Not only 
the incidence, but also the characteristics of the tumours can change. Those changes could 
be a result of changing sun-exposure habits or a change in screening efforts. A specific in-
depth registration of characteristics of melanomas is the only possibility to give us that infor-
mation. 
This study identified a small scale effect of the intervention on the melanoma incidence in 
males, but not in females and without any effect on the distribution of the tumour stages. This 
intervention was targeted at the population as a whole. It has been suggested that effective-
ness of skin cancer screening may be higher if targeted at high-risk persons only. We 
therefore consider targeting our actions in the future at people who are at increased risk, ei-
ther by their personal skin characteristics or by occupation. This especially includes people 
frequently working in open air. Selection of such high risk people can easily be done by oc-
cupational medicine and by general practitioners. As dermatologists may be better qualified 
to identify melanoma and atypical naevi compared to non-dermatologists (11), the use of 
dermatoscopy by non-specialised clinicians may improve their yield, at least in selecting pa-
tients with an increased risk of abnormality from the large bunch of patients with a clearly 
normal picture (12). Pre-selected patients may then be more efficiently examined by derma-
tologists. 
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